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Abstract
Alzheimer’s disease is a chronic progressive disease for which there is no cure.
Pharmacotherapy used in treatment of the disease does not modifry the disease but
instead provides symptomatic relief. These drugs are known to be effective in early
stages of the disease but they are not without side effects. Drugs are often continued
into moderate and severe stages of the disease. This literature review found that 5
studies indicated there was no significant change in MMSE scores in subjects who
continued and discontinued acetylcholinesterase therapy in moderate and severe AD.
The review of the literature found contradictory evidence on whether there was a
difference in side effects and quality of life based off of treatment. The amount of
contradictory evidence suggests it is worthwhile to consider discontinuing
pharmacotherapy on a case by case basis in late disease

Introduction
AD is a chronic and ultimately fatal condition. It is a progressive and
irreversible disease that is characterized by damage to brain cells. Damage
takes place in the form of neurofibrillary tangles, , inflammation and amyloid
plaques. AD impairs cognition, functional, and physical ability. There is no
cure or disease modifying treatment for AD. However there is a typical
regiment of drugs employed to treat AD symptoms. At early stages these rugs
are effective however their efficacy decreases as the disease progresses. These
medications have side effects and there is currently no standard of care
recommendation for when these drugs should be discontinued. This review
analyzes whether or not evidence suggests these drugs should continue to be
utilized in late term disease.

Methods
A Literature search was performed using Pubmed and Google
Scholar in November of 2019. A total of 5 articles that were all
randomized controlled trials were selected based on the criteria of
trial time, population type, date, and experimental variable type.
The designs of these five studies in addition to their results and the
quality of the design were then analyzed and compared

Results
The evidence collected from analyzing the studies was contradictory. The one finding
that was not contradictory between studies was that there as not a significant change in
MMSE score between groups that continued pharmacotherapy and groups that
discontinued therapy or recieved a lower dose. The five studies had contradictory
findings when they compared whether or not pharmacotherapy had a significant effect
on the symptoms and effect of the illness at late disease stages and whether or not the
side effects were significant compared to no treatment at all and treatment at lower
doses.

Discussion
In two of the five studies there was a significant difference in the effect of
the disease between the treatment and control groups, however, in two of
the five studies it was found that there was not a significant difference
between the experimental and control groups. In addition, one of the
studies found there was a significant impact of side effects on the quality
o f life of the subject and another study found the side effect presence was
not significantly different between the experimental and control group.
Further study of this topic should be done to better determine the effects
of the drug in late stages of Alzheimer’s disease and whether or not these
effects outweigh the side effects enough to justify continued use.

Table 1. Comparison of Results
Conclusion
Acetylcholinesterase inhibitors are routinely used for the treatment of the
symptoms of AD. Despite this, very few trials have effectively tested
whether or not it is good standard of care to continue the use of these drugs
in the late stages of the disease. The five studies found contradictory
evidence reguarding thais question. While the evidence suggests it is
worthwhile to re-examine the costs and benefits of such treatment in each
patient to consider discontinuation as the disease progresses, more studies
are needed before a definitive conclusion can be made.
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